In the present invention inventors used measured cytokine levels in serum of patients with COVID-19, at the time of hospital admission. Thereafter, inventors used a non-supervised bioinformatics approach to identify the cytokine combinations that represent a reliable biomarker of COVID-19-related severity and/or mortality. Briefly cytokine concentrations were measured at hospital admission in serum of symptomatic COVID-19 patients (N=115), classified at hospitalization into three respiratory severity groups: moderate severity with no need for mechanical ventilatory support (No-MVS), intermediate severity requiring mechanical ventilatory support (MVS) and critical severity requiring extracorporeal membrane oxygenation (ECMO). More specifically present invention relates to methods for prognosis and/or classification and/or stratification and/or monitoring of the pulmonary critical form of coronavirus disease and/or of critically severe coronavirus disease through comparison of specific cytokine combinations in a COVID-19 patient. The present invention also relates to a method of treating a coronavirus disease in a subject in need thereof by guiding a precision medicine approach through detection of specific cytokine profiles in a patient.